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1. Disease characteristics 
1.1 Name of the Disease (Synonyms): 
Wolfram Syndrome (WFS). Clinically, WFS presents with two clinical subtypes, namely 
WFS1 (Diabetes insipidus and mellitus with optic atrophy and deafness, DIDMOAD), and 
WFS2. 
 
1.2 OMIM# of the Disease:  
222300- Wolfram Syndrome 1  
604928- Wolfram Syndrome 2 
598500- Mitochondrial form 
 
1.3 Name of the Analysed Genes or DNA/Chromosome Segments: 
Genes implicated in Wolfram syndrome type 1: WFS1  
Genes implicated in Wolfram syndrome type 2: CISD2 
 
1.4 OMIM# of the Gene(s): 
WFS1 MIM# 606201  
CISD2 MIM# 611507  
 
1.5 Mutational Spectrum: 
Wolfram syndrome 1 (WFS1) is an autosomal recessive progressive neurodegenerative 
disease characterized by early-onset type 1 diabetes mellitus (DM) and bilateral optic 
neuropathy (OA) with a wide spectrum of associated clinical conditions described below. 
Over 90% of variants are found in the WFS1 gene, which spans 33.4 kb on chromosome 
4p16.1, and consists of 8 exons encoding the 890-amino acid Wolframin protein (NCBI 
reference sequence NM_006005.3, NM_001145853), that localises to the endoplasmic 
reticulum (ER). Current evidence suggests that Wolframin is a component of mitochondria-
associated membranes (MAMs) and may play an important role in regulating ER-
mitochondria homeostasis.(1) There have been over 250 variants in WFS1 described in 
patients with Wolfram Syndrome, WFS1 (https://lovd.euro-wabb.org). Reported variants are 
mainly point mutations (missense, nonsense, frameshift mutations), but also small deletions, 
insertions and duplications. 
 
Wolfram syndrome 2 (WFS2) is also recessively inherited with considerable overlap of 
clinical features with WFS1, it is classically associated with peptic ulcer disease and bleeding 
tendencies without diabetes insipidus (DI). It is caused by variants in the CISD2 (CDGSH 
Iron Sulfur Domain 2) gene on chromosome 4q24, which consists of 3 exons encoding the 
endoplasmic reticulum intermembrane small (ERIS) protein. Reported variants include a 
missense mutation in Jordanian families suggestive of a founder event and a deletion in one 
non-consanguineous Italian family.(2-4) 
 
There has been a suggested link between mitochondrial DNA (mtDNA) mutations and 
WFS.(5) A 7.6 kb heteroplasmic deletion (spanning nucleotides 6465-14135) has been 
reported(6), in addition to multiple deletions of mtDNA and a point mutation (m.3337G>A) in 
the mitochondrial gene encoding subunit ND1 in a Tunisian patient.(7) In some patients with 
WFS1 variants, secondary mtDNA instability can be found particularly in post-mitotic tissues 
such as skeletal muscle, and this may contribute to the more severe clinical 
manifestations.(8, 9) 
 
It is important to note that Wolfram-like syndrome (OMIM 614296) also exists with 
overlapping features. This is an autosomal dominant disorder caused by heterozygous 
variants in WFS1, resulting in sensorineural hearing loss, diabetes mellitus, psychiatric 
illness, and variable optic atrophy within the first decade of life.(10, 11)  
 
1.6 Analytical Methods: 
Bi-directional fluorescent Sanger sequencing of coding and intron–exon boundaries of WFS1 
is the mainstay analytical method as an initial analysis. CISD2 screening can be performed if 
WFS2 is suspected, as this is rare. However, WFS1 and CISD2 screening is being included 
on next generation sequencing (NGS) panels in some laboratories. 
 
1.7 Analytical Validation 
Parallel bi-directional fluorescent Sanger sequencing of known controls is required to validate 
procedures. Diagnostic testing must be carried out within a laboratory environment working 
to standards compliant with the ISO 15189. The majority of variants reported to date in the 
WFS1 gene causing autosomal recessive Wolfram syndrome result in loss-of-function.(12)  
 
1.8 Estimated Frequency of the Disease 
(Incidence at birth ("birth prevalence") or population prevalence. If known to be variable 
between ethnic groups, please report): 
Estimated prevalence of 1 in 770,000 in the UK(13), 1 in 100 000 in North America(14), 1 in 
500 000 in children(15), and 1 in 68 000 in the Lebanese population (possibly attributable to 
high rates of consanguinity).(16) Carrier frequency is 1 in 354 patients.(13)  
 
1.9 Diagnostic Setting: 
 Yes. No. 
A. (Differential) diagnostics    
B. Predictive Testing    
C. Risk assessment in Relatives    
D. Prenatal    
 
Comment: If a family has an affected child and wishes to have more children, prenatal 
diagnosis should be discussed in detail during genetic counseling.(17) 
 
2. Test characteristics 
 
 
2.1 Analytical Sensitivity 
(proportion of positive tests if the genotype is present) 
We estimate that the analytical sensitivity and specificity of the test used (bi-directional 
Sanger sequencing) will be >98%. A small loss of sensitivity may be due to intronic or other 
variants missed through exonic analysis. The proportion of such cases is not known. 
 
2.2 Analytical Specificity 
(proportion of negative tests if the genotype is not present) 
See above. We estimate analytical specificity of >98% given current testing methodologies, 
based on the false positives that can rarely occur in Sanger sequencing.  
 
2.3 Clinical Sensitivity 
(proportion of positive tests if the disease is present) 
The clinical sensitivity can be dependent on variable factors such as age or family history. In 
such cases a general statement should be given, even if a quantification can only be made 
case by case. 
If a patient has both DM and OA before 16 years of age, in the presence of a positive genetic 
test, the clinical sensitivity and specificity are both high as WFS type 1 and 2 are not 
genetically heterogeneous, with WFS1 accounting for >90% of WFS1 and CISD2 causing 
WFS2.(18) However, due to the variable order and age of onset of different clinical features, 
care has to be taken with the interpretation of heterozygous variants in WFS1, which cause 
Wolfram-like syndrome disorders, including missense mutations associated with autosomal 
dominant OA and sensorineural hearing loss (SNHL),(10, 19) autosomal dominant 
nonsyndromic adult-onset diabetes(20), psychiatric symptoms and autosomal dominant low-
frequency nonsyndromic SNHL.(21)  
 
In a systematic review analysing the published clinical data in 392 patients with WFS, 98.2% 
had DM and 82.14% developed OA.(12)  By age 18, the probability of having developed the 
DM is 93.60%, OA 79.06%, SNHL 40.56%, DI 35.20%, urinary defects 11.42% and 
neurological, psychiatric or developmental problems 7.57%.(12)  
 
2.4 Clinical Specificity 
(proportion of negative tests if the disease is not present) 
The clinical specificity can be dependent on variable factors such as age or family history. In 
such cases a general statement should be given, even if a quantification can only be made 
case by case. 
 
An individual without signs of DM and OA is unlikely to have a positive test as both clinical 
manifestations can be seen in the majority (90%) by the second decade (14–15 years of age 
for DM and at 25–26 years for OA), this increases to 95% probability at 23–24 years for DM 
and at 40–41 years for OA,(12) and so the clinical specificity will be high. However, in some 
cases the onset of clinical features is variable and this can lower the clinical specificity. 
 
2.5 Positive clinical predictive value 
(life time risk to develop the disease if the test is positive) 
Estimated >99% for two pathogenic alleles in WFS1 and CISD2. A genotype-phenotype 
correlation has been suggested for WFS1 variants in determining the age at onset of DM and 
DI in type 1 WFS.(12)  
 
2.6 Negative clinical predictive value 
(Probability not to develop the disease if the test is negative). 
Assume an increased risk based on family history for a non-affected person. Allelic and locus 
heterogeneity may need to be considered.  
Index case in that family had been tested: 
For known pathogenic changes, or novel null mutations, the negative predictive value will be 
approaching 100%. 
 
Index case in that family had not been tested: 
If the index case is asymptomatic by 16 years of age and has a negative test result, it is 
highly predictive of unaffected status, but will fall short of 100% due to the analytical 
specificity noted above.  
 
 3. Clinical Utility 
3.1 (Differential) diagnostics: The tested person is clinically affected 
       (To be answered if in 1.9 "A" was marked) 
3.1.1 Can a diagnosis be made other than through a genetic test? 
 
No.  (continue with 3.1.4) 
Yes,  
 clinically.   
 imaging .  
 endoscopy.   
 biochemistry.   
 electrophysiology.  
other (please describe): 
 
 
 
3.1.2 Describe the burden of alternative diagnostic methods to the patient 
WFS1 is a progressive neurodegenerative disorder characterized by the onset of diabetes 
mellitus around the age of 6 (range 3 weeks - 16 years), with optic atrophy developing 
typically by age 11 (range 6 weeks - 19 years).(22) It is commonly associated with high 
frequency sensorineural hearing loss (62%), which presents around age 16 (range 5-19 
years).(13) Progressive neurologic abnormalities (60%, including cerebellar ataxia, 
peripheral neuropathy, dementia, psychiatric illness), urinary tract defects (60-90%, including 
ureteric obstruction, bladder atony and sphincter dyssynergia, and incontinence), and other 
endocrine abnormalities associated with pituitary dysfunction such as hypogonadism and 
diabetes insipidus (51-87%) presenting around age 14 (range 3 months - 40 yrs).(22) The 
median age of death is 27 ± 11.4 years.(12)  
 
Patients with WFS2 have overlapping features with WFS1, plus defective platelet 
aggregation resulting in peptic ulcer bleeding, but importantly an absence of diabetes 
insipidus.(2, 23) 
 
Children who are suspected of having WFS will undergo a number of investigations including 
MRI of the brain and orbit to look for generalized brain atrophy (cerebellum, medulla, and 
pons); absence of signal from the posterior pituitary; and reduced signal from the optic 
nerve.(24) Ancillary testing can be useful to confirm primary retinal ganglion cell dysfunction. 
Electrophysiology tests such as visual evoked potentials (VEPs) and the pattern 
electroretinogram (ERG) provide objective measures of optic nerve funcion, and optical 
coherence tomography (OCT) is a non-invasive ocular imaging modality that is frequently 
used to quantify and monitor progressive thinning of the retinal nerve fibre layer. Hearing 
tests such as pure tone audiometry document affected frequencies and progression of 
hearing loss. Tests for DI include urine analysis, the water deprivation test, blood levels of 
antidiuretic hormone (ADH) and the ADH test to differentiate cranial versus nephrogenic DI.  
 
Genetic testing can assist the clinical surveillance as pathogenic variants in WFS1 or CISD2 
would justify pre-symptomatic regular follow-up by ophthalmologists, audiologists, 
endocrinologists and neurologists in order to provide the appropriate support to the patient 
and their family.  
 
3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?  
Although WFS is a rare disorder, it is associated with significant multisystem co-morbidity 
and a short life expectancy. Making the correct diagnosis early is therefore important to 
optimize the management of neurological and endocrine complications, which can be life-
threatening and ensure appropriate support and rehabilitation. Clinical recognition can be 
challenging due to the varying onset of signs and symptoms, especially for physicians in non-
specialist centres who do not manage the disease regularly. Patients will often require 
tertiary referral for accurate diagnosis. Genetic testing is important for accurate diagnosis, 
however, multidisciplinary team input will still be required for regular monitoring of clinical 
manifestations.  
3.1.4 Will disease management be influenced by the result of a genetic test? 
No.  
 
Yes.  
 Therapy (please describe)  No treatment is currently available for WFS, only 
supportive measures. However, preclinical work has identified that WFS is an 
endoplasmic reticulum (ER) disease with increased calpain-2 linked to the 
mechanism of neuronal cell death. Dantrolene, a small molecule drug, has been 
shown to prevent cell death in neural progenitor cells derived from WFS-induced 
pluripotent stem cells suggesting that inhibition of calpain and its activation may 
provide a therapeutic target.(25)  
 
The group of Christian Hamel (INSERM, Montpellier, France) is also developing an 
AAV2-based viral vector to rescue RGCs.  The results are promising. 
 
Prognosis (please describe)  Once affected status is known, the specific genotype 
may be able to indicate the age of onset of DM and DI, these are predictive but not 
conclusive genotype–phenotype correlations.(12)  
 
 Management (please describe) Genetic counselling will be offered to the family and 
multidisciplinary care team and social services involvement to support ensuing 
disabilities as they arise. 
 
3.2 Predictive Setting: The tested person is clinically unaffected but carries an 
increased risk based on family history 
     (To be answered if in 1.9 "B" was marked) 
3.2.1 Will the result of a genetic test influence lifestyle and prevention? 
If the test result is positive (please describe) There is currently no effective treatment for 
WFS. General advice would be to stop 
smoking and alcohol consumption, maintain a 
healthy diet with vitamins. A positive genetic 
test may inform family planning. Patients 
develop a range of disabilities over the 
proceeding years with a 60% mortality rate by 
the age of 30. This will greatly influence the 
choice of career and life planning. 
 
If the test result is negative (please describe) The result may influence choice of career and 
inform family planning. General advice 
pertains to minimise morbidity, including no 
smoking and limit alcohol consumption whilst 
maintaining a healthy diet with vitamins.  
3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no 
genetic test has been done (please describe)? 
 
Patients with WFS have a poor visual prognosis, usually less than 6/60 (or 20/200) 
secondary to optic atrophy, therefore professions requiring perfect vision are impossible. 
Hence, a clinically confirmed diagnosis can already help in providing guidance regarding 
career choice.  
 
3.3 Genetic risk assessment in family members of a diseased person 
     (To be answered if in 1.9 "C" was marked) 
3.3.1 Does the result of a genetic test resolve the genetic situation in that family? 
Yes, a molecular diagnosis in an affected individual can resolve the genetic situation in that 
family, determine recessive segregation unambiguously and is a prerequisite for genetic 
counselling for family members. For Wolfram-like syndrome, where de novo heterozygous 
variants in WFS1 are found, the recurrence risk is low but there is a high offspring risk of 
50%. 
 
3.3.2 Can a genetic test in the index patient save genetic or other tests in family 
members? 
If molecular testing has identified a WFS1 mutation in the index patient, depending on age, 
examination can identify and exclude disease in at-risk relatives. However, further genetic 
tests are required to determine the carrier status. It is important to consider that 
heterozygous variants in WFS1 can cause Wolfram-like syndrome (section 2.3), and 
autosomal dominant cataracts,(26) so patients must be examined to exclude any 
manifestations. This must be undertaken following genetic counselling and arguably when 
the patient can make their own decision. 
 
3.3.3 Does a positive genetic test result in the index patient enable a predictive test in 
a family member? 
Yes 
 
3.4 Prenatal diagnosis 
     (To be answered if in 1.9 "D" was marked) 
3.4.1 Does a positive genetic test result in the index patient enable a prenatal 
diagnosis? 
Yes 
 
4. If applicable, further consequences of testing 
Please assume that the result of a genetic test has no immediate medical consequences. Is 
there any evidence that a genetic test is nevertheless useful for the patient or his/her 
relatives? (Please describe) 
Genetic testing for WFS1 variants will provide a molecular diagnosis. This yields information 
regarding onset of symptoms, recurrence risk, carrier status and hence will provide choices 
that would not otherwise be available to facilitate decision making for the patient and their 
family. Gene testing is essential in defining inheritance patterns and enabling effective 
genetic counselling. A positive gene test will preclude the need for further genetic testing. 
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